Dose-intensive chemotherapy in advanced adult soft tissue sarcoma

Expert Review of Anticancer Therapy

Volumn 2, Issue 2, 2002, Pages 201-215

  Verma, Shailendra ^a   Bramwell, Vivien ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

High dose chemotherapy; Metastatic; Sarcoma; Soft tissue

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IFOSFAMIDE; MESNA; MITOMYCIN; VINCRISTINE;

ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARCINOMA IN SITU; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG MEGADOSE; DRUG RESPONSE; EARLY CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION RISK; METASTASIS; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUROTOXICITY; ONCOLOGY; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

EID: 0036084339     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.2.201     Document Type: Review

References (103)

1. Cancer Statistics
2. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group
3. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities
4. Cellular DNA content and prognosis of high grade soft tissue sarcoma. The Scandinavian Sarcoma Group Experience
5. The Italian registry of soft tissue tumors
6. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients
7. Prognostic factors in soft tissue sarcomas: The aarhus experience
8. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically treated patients from the Scandinavian Sarcoma Group Register
9. Patterns of recurrence in patients with high grade soft tissue sarcomas
10. Soft-tissue sarcoma: Initial characteristics and prognostic factors in patients with and without metastatic disease
11. Lymph node metastasis from soft tissue sarcoma in adults: Analysis of data from a prospective database of 1772 sarcoma patients
12. A clinical and pathological staging system for soft tissue sarcoma
13. The treatment of soft tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy with amputation and (2) the role of adjuvant chemotherapy
14. The management of soft-tissue sarcomas of the extremities
15. Surgical treatment of 297 soft tissue sarcomas of the lower extremity
16. Retroperitoneal soft-tissue sarcoma: Analysis of 500 patients treated and followed at a single institution
17. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity
18. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma
19. Preoperative, intraoperative and postoperative radiation in the treatment of primary soft tissue sarcoma
20. Phase III randomized trial of preoperative versus postoperative radiotherapy in the curative management of extremity soft tissue sarcoma
21. Adjuvant adriamycin (doxorubicin) in adult patients with soft-tissue sarcomas: A systemic overview and quantitative meta-analysis
22. Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremeties
23. Adjuvant chemotherapy for soft-tissue sarcoma: Review and meta-analysis of the published results of randomized clinical trials
24. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: Meta-analysis of Individual Data
25. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized co-operative trial
26. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: A prospective randomized feasibility trial
27. Epirubicin alone or epirubicin + ifosfamide as adjuvant chemotherapy in soft tissue sarcomas
28. Pulmonary metastasectomy for soft tissue sarcomas: Is it justified?
29. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group Study of 255 patients
30. Pulmonary metastases from soft tissue sarcoma
31. Results of single agent and combination chemotherapy for advanced soft tissue sarcoma. Implications for decision making in the clinic
32. Dose response evaluation of Adriamycin in human neoplasia
33. Doxorubicin-based combination chemotherapy for palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma
34. Adriamycin versus epirubicin in advanced soft tissue sarcomas: A randomized phaseII/Phase III study of the EORTC Soft Tissue and Bone Sarcoma Group
35. High dose epirubicin is not an alternative to standard dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma group
36. Ifosfamide
37. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma
38. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma
39. Ifosfamide in the treatment of soft tissue sarcomas: Experience at the West German Tumour Centre. Essen
40. Cyclophosphamide versus ifosfamide. Final report of a randomized Phase II trial in adult soft tissue sarcoma
41. Randomized Phase II study of the EORTC Soft Tissue and Bone sarcoma Group (STBSG) comparing two different ifosfamide (IF) regimens in chemotherapy untreated advanced soft tissue sarcoma (STS) patient (pts)
42. High-dose ifosfamide in bone and soft tissue sarcomas: Results of Phase II and pilot studies - Dose response and schedule dependence
43. Randomized comparison of three adriamycin regimens for metastatic soft issue sarcomas
44. Combination chemotherapy with adriamycin and streptozotocin 1. Clinical results in patients with advanced sarcoma
45. A comparison of adriamycin versus vincristine and adriamycin and cyclophosphamide versus vincristine, actinomycin-D and cyclophosphamide for advanced sarcoma
46. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas
47. Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide
48. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft tissue sarcomas
49. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas
50. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of cancer Soft Sarcoma group
51. Randomized study of high dose epirubicin versus high dose epirubucin-cisplatin chemotherapy for advanced soft tissue sarcoma
52. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas
53. Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas
54. Combination of consecutive low-dose (CLD) cisplatin with ifosfamide and epirubicin (CLD-IEP) for sarcoma uteri
55. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: Results of a Phase II study
56. Phase II evaluation of doxorubicin, ifosfamide and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcoma
57. Dose-intensive first line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: A Phase II study
58. Phase II trial of ifosfamide, cisplatin and doxorubicin in advanced soft tissue sarcoma in adults
59. Dose-intensive chemotherapy with ifosfamide, epirubicin and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A Phase II study
60. Epirubicin and ifosfamide in advanced soft tissue sarcoma: A Phase II study
61. Epirubicin and ifosfamide in advanced soft tissue sarcomas
62. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma
63. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment Tissue and Bone Sarcoma Group
64. Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas
65. Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas
66. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma
67. Combination chemotherapy with doxorubicin, dacarbazine and ifosfamide in advanced adult soft tissue sarcoma
68. Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi-institutional Phase II trial
69. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcomas and consequences on treatment dose intensity
70. Accelerated epirubicin-dacarbazine regimen in patients with adult soft tissue sarcomas
71. Doxorubicin plus ifosfamide with rhGMCSF in the treatment of advanced adult soft-tissue sarcomas: Preliminary results of a Phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group
72. Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rhu-G-CSF) in patients with advanced soft tissue sarcomas
73. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II study
74. Increasing 4′ epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A pilot study
75. Phase I multicenter study of combined high dose ifosfamide and doxorubicin in the treatment of advanced sarcomas
76. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors
77. A Phase I/II study of sequential dose escalated high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas
78. Effect of high dose ifosfamide in advanced soft tissue sarcomas. A multicentre Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
79. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas
80. High-dose ifosfamide in the treatment of advanced soft tissue sarcomas
81. Failure of continuous infusion high dose ifosfamide as second line treatment for sarcomas: Poor response rate and unacceptable renal and CNS toxicity
82. Phase II trial of first-line high-dose ifosamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)
83. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?
84. Dose-intensive chemotherapy with ifosfamide, epirubicin and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A Phase II study
85. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: A Phase II study
86. Dose intensive chemotherapy with adriamycin, ifosfamide and growth factors in chemotherapy-naive patients with sarcomas
87. High dose chemotherapy with autologous hematopoietic stem-cell transplantion for advanced soft tissue sarcoma in adults
88. Randomized Phase III study comparing conventional-dose doxorubicinplus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
89. qMAID vs. MAID + 25% with G-CSF in adults with advanced soft tissue sarcoma (STS). First results of a randomized study of the FNCLCC sarcoma group
90. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide
91. Randomized Phase II trial of pegylated liposomal doxorubicin (Doxil®/Caelyx®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
92. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571 in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117)
93. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC Phase I study
94. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
95. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas. Final results of Phase II and pharmacokinetic studies in the USA
96. ET-743 is an active drug in adult soft tissue sarcoma - A STBSG-EORTC Phase II trial
97. Ecteinascidin (ET743) given as a 24 h iv. continuous infusion every 3 weeks: Results of a Phase II trial in patients with pretreated soft tissue sarcomas
98. Docetaxel plus gemcitabine is active in leiomyosarcoma: Results of a Phase II trial
99. A Phase II trial of gemcitabine paclitaxel and carboplatin in stage IV B soft tissue sarcoma
100. Differentiation of liposarcomas in patients treated with PPAR γ ligand troglitazone: Documentation of biologic activity in myxoid/round cell and pleomorphic subtypes